Early diagnosis of antibody-mediated rejection (AMR) is critical to preventing irreversible damage to transplanted organs and improving patient outcomes. In recent years, advancements in diagnostic techniques have significantly enhanced the ability to detect AMR at earlier stages, allowing for more effective interventions. The AMR diagnostic market is evolving as researchers and clinicians strive to improve diagnostic accuracy, speed, and accessibility.

The antibody-mediated rejection market is estimated to be valued at USD 126.5 Mn in 2024 and is expected to reach USD 291.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.64% from 2024 to 2031.

Traditional Diagnostic Methods

Traditionally, the diagnosis of Antibody-Mediated Rejection Market has relied on histological examination of biopsy samples from the transplanted organ. This approach, while effective, is invasive and may not always detect AMR in its early stages. Histological examination typically reveals changes in the tissue that suggest rejection, such as inflammation and microvascular injury. However, by the time these changes are visible, irreversible damage to the organ may already have occurred.

Molecular Diagnostics

Recent advances in molecular diagnostics are revolutionizing the detection of AMR. Researchers are focusing on developing blood-based tests that can detect the presence of donor-specific antibodies (DSAs), which are the primary cause of AMR. These tests can identify AMR much earlier than histological examination, allowing for timely intervention and reducing the risk of transplant failure.

➣ Get More Insights On-Antibody-Mediated Rejection Market

➣ Get this Report in Japanese Language: 抗体介在拒絶反応市場

➣ Get this Report in Korean Language:   항체 매개 거부 반응 시장